Seqens Seqens

X
[{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolve Biologics\u00ae Completes Phase III Adult and Pediatric Trials for Plasmacap\u2122 Ig (Intravenous Immunoglobulin)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Evolve Biologics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCap IG in adults and children with primary immune deficiency disease met all primary and secondary endpoints.

            Lead Product(s): Human Immunoglobulin

            Therapeutic Area: Immunology Product Name: PlasmaCap IG

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY